OakChart

Larimar Therapeutics Inc

LRMRHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.73+0.04 (1.49%)
2026-11-11 22:46 CET
Market cap
280.79 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-172.60 USD m
Free cash flow, TTM
-156.08 USD m
EPS diluted, TTM
-1.98
P/E
-
Compare

Price

LRMR against its 20, 50 and 200-day averages
2050200beat
2.003.004.006.7M13.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LRMRclose 2.7320-day 2.4150-day 2.97200-day 3.772.7352w low

57.5% under the 52-week high of 6.42 on 25 Feb 2026. 52-week low 1.92 on 16 Oct 2026. Last 15 sessions, 29.8% high to low

Volume 0.88× normal · the line is the 50-bar volume average

Profile

LRMR
52-week range, 18% of the way up
1.916.42

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. It also engages in the research, development, and commercialization of novel therapeutics for mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

IndexRUT
Employees71
IPOJun 19, 2014
Beta0.68
ATR, 14d0.24
Rel volume0.88
Short float21.95%
Insider own54.01%
Inst own51.60%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap283.61M
Enterprise Value132.30M
Income-172.60M
Sales0.00M
Book/sh1.22
Cash/sh1.50
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees71
IPOJun 19, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.24
P/C1.81
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.70
Current Ratio4.70
Debt/Eq0.04
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.98
EPS next Y-1.18
EPS next Q-0.35
EPS this Y39.02%
EPS next Y14.67%
EPS next 5Y38.33%
EPS past 3/5Y-18.15% 8.74%
Sales past 3/5Y- -
EPS Y/Y TTM-27.00%
Sales Y/Y TTM-
EPS Q/Q23.18%
Sales Q/Q-
EarningsAug 04 BMO
EPS/Sales Surpr.21.36% -

Ownership

Insider Own54.01%
Insider Trans0.09%
Inst Own51.60%
Inst Trans11.15%
ROA-109.49%
ROE-139.63%
ROIC-131.62%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2013.24%
SMA50-8.17%
SMA200-27.64%
Trades-

Technical

Shs Outstand103.88M
Shs Float48.00M
Short Float21.95%
Short Ratio8.02
Short Interest10.54M
52W High6.42 -57.48%
52W Low1.91 42.56%
Volatility12.21% 10.81%
ATR (14)0.24
RSI (14)52.98
Beta0.68
Rel Volume0.88
Avg Volume1.31M
Volume1,156,903

Performance

Perf Week-1.09%
Perf Month26.39%
Perf Quarter-36.07%
Perf Half Y-33.41%
Perf YTD-28.35%
Perf Year-24.79%
Perf 3Y11.43%
Perf 5Y-78.16%
Perf 10Y-93.50%
Recom1.09
Target Price14.40
Prev Close2.69
Price2.73
Change %1.49%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Sep 14, 2026ResumedLLeerink PartnersOutperform$13+376.2%
Jul 02, 2026ResumedHH.C. WainwrightBuy$10+266.3%
May 27, 2026InitiatedJJP MorganOverweight$9+229.7%
Jan 29, 2025InitiatedTTruistBuy$18+559.3%
Oct 16, 2024InitiatedOOppenheimerOutperform$26+852.4%
Oct 03, 2024InitiatedWWedbushOutperform$22+705.9%
Oct 02, 2024InitiatedHH.C. WainwrightBuy$15+449.5%
Sep 04, 2024InitiatedRRobert W. BairdOutperform$16+486.1%
Apr 03, 2024InitiatedLLeerink PartnersOutperform$25+815.8%
Nov 17, 2023UpgradeCCitigroupNeutral → Buy$4.50+64.8%

Peers

Mkt cap
TickerCompanyMkt cap
DSGNDesign Therapeutics Inc689.67M
LXEOLexeo Therapeutics Inc252.01M
SLDBSolid Biosciences Inc848.24M
RAREUltragenyx Pharmaceutical Inc1.70B
SRPTSarepta Therapeutics Inc1.79B
WVEWave Life Sciences Inc674.52M
DYNDyne Therapeutics Inc3.37B
PEPGPepGen Inc364.31M
STOKStoke Therapeutics Inc1.82B
ZVRAZevra Therapeutics Inc705.13M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Hamilton Thomas EdwardDirectorJul 06 '26Buy3.3450,000166,890714,798Jul 08 04:05 PM
Flynn James EDirectorFeb 27 '26Buy5.005,000,00025,000,00010,622,957Mar 02 07:46 PM
Hamilton Thomas EdwardDirectorFeb 27 '26Buy5.00100,000500,000664,798Mar 02 04:30 PM
THOMAS FRANK EDirectorFeb 27 '26Buy5.005,00025,0007,000Mar 02 04:30 PM
SHERMAN JEFFREY WDirectorFeb 27 '26Buy5.005,00025,0005,000Mar 02 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-04-0.300-0.382-0.3000.000.0011
2026Q12026-05-14-0.310-0.535-0.3280.000.008
2025Q42026-03-19-0.730-0.489-0.7320.000.0011
2025Q32025-11-05-0.610-0.404-0.6090.000.0011
2025Q22025-08-14-0.410-0.480-0.4090.000.0011
2025Q12025-04-30-0.460-0.418-0.4580.000.0011
2024Q42025-03-24-0.450-0.317-0.4520.000.0012
2024Q32024-10-30-0.240-0.375-0.2430.000.0011
2024Q22024-08-07-0.340-0.305-0.3390.000.006
2024Q12024-05-09-0.270-0.244-0.2740.000.005
2023Q42024-03-14-0.300-0.248-0.2960.000.005
2023Q32023-11-14-0.210-0.223-0.2060.000.005
2023Q22023-08-10-0.190-0.195-0.1910.000.005
2023Q12023-05-15-0.150-0.248-0.1490.000.005
2022Q42023-03-14-0.210-0.374-0.2150.000.005
2022Q32022-11-10-0.370-0.420-0.3740.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-14.640-16.200-45.571-0.00
2020FY-3.570-2.760-3.5750.000.00
2021FY-2.950-3.027-2.9500.000.00
2022FY-1.370-1.672-1.3720.000.00
2023FY-0.840-0.744-0.8420.000.00
2024FY-1.320-1.209-1.3160.000.00
2025FY-2.270-1.952-2.2700.000.00
2026FY--1.384--0.00
2027FY--1.181--41.74
2028FY--0.532--130.36
2029FY-0.520--326.03
2030FY-1.557--484.45

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-098000.000.000.00
2026Q3S2026-10-097000.000.000.00
2026Q3S2026-08-048000.000.000.00
2026Q3S2026-07-018000.000.000.00
2026Q3S2026-05-267000.000.000.00
2026Q3S2026-05-146000.000.000.00
2026Q3S2026-04-216000.000.000.00
2026Q3S2026-03-195000.000.000.00
2026Q3S2025-11-116000.000.000.00
2026Q3S2025-11-106000.000.000.00
2026Q3S2025-11-096000.000.000.00
2026Q3S2025-11-086000.000.000.00
2026Q3S2025-11-076000.000.000.00
2026Q3S2025-11-066000.000.000.00

Estimate history

EPS, annual-22.758-22.85-45.571-3.575-2.95-1.372-0.842-1.316-2.263-1.9829
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.339-0.243-0.452-0.458-0.409-0.609-0.732-0.328-0.314
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual2.2913.1070.50815.36817.7143.26943.90963.81583.34104.383
Period201720182019202020212022202320242025MRQ
Shares, quarterly63.80363.80763.81564.02864.02885.5983.34104.383104.383
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.300.350.320.310.270.330.150.080.26
Gross Profit-0.30-0.35-0.32-0.31-0.27-0.33-0.15-0.08-0.26
Selling, General and Administrative Excl. Other178.68172.1590.5741.4536.2550.1442.6523.1462.46
Research and Development157.03153.8772.9627.3623.9838.0731.2520.7149.53
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-178.99-172.50-90.89-41.76-36.53-50.47-42.80-23.21-62.72
Interest Expense0.000.000.000.000.000.000.000.001.90
Unusual Expense0.000.000.000.000.000.000.000.00-
Net Income Before Taxes-172.60-165.67-80.60-36.95-35.35-50.64-42.48-23.13-62.97
Income Taxes0.000.000.000.000.000.000.000.00-1.60
Consolidated Net Income-172.60-165.67-80.60-36.95-35.35-50.64-42.48-23.13-61.37
Net Income From Continuing Operations-172.60-165.67-80.60-36.95-35.35-50.64-42.48-23.13-61.37
Net Income-172.60-165.67-80.60-36.95-35.35-50.64-42.48-23.13-61.37
EPS (Recurring)-1.65-2.26-1.32-0.84-1.37-2.95-3.57-45.57-22.85
EPS (Basic, Before Extraordinaries)-1.98-2.26-1.32-0.84-1.37-2.95-3.58-45.57-22.85
EPS (Diluted)-1.98-2.26-1.32-0.84-1.37-2.95-3.58-45.57-22.85
EBITDA-178.68-172.15-90.57-41.45-36.25-50.14-42.65-23.14-62.46
Non-Operating Income (Expense)6.386.8210.294.811.17-0.170.320.081.65
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.477.008.807.626.625.472.160.139.63
Shares Outstanding104.3883.3463.8243.9143.2717.7115.370.513.11
Market Capitalization280.79280.79246.93199.77178.70191.10328.7841.57184.57

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.060.060.090.090.090.090.080.07
Gross Profit-0.06-0.06-0.09-0.09-0.09-0.09-0.08-0.07
Selling, General and Administrative Excl. Other34.2931.0563.9349.4127.7031.1031.2218.19
Research and Development27.9424.9759.2944.8423.2826.4626.6613.85
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-34.35-31.12-64.02-49.50-27.79-31.19-31.29-18.26
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-32.78-29.61-62.50-47.71-26.18-29.28-28.82-15.50
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-32.78-29.61-62.50-47.71-26.18-29.28-28.82-15.50
Net Income From Continuing Operations-32.78-29.61-62.50-47.71-26.18-29.28-28.82-15.50
Net Income-32.78-29.61-62.50-47.71-26.18-29.28-28.82-15.50
EPS (Recurring)-0.31-0.33-0.73-0.61-0.41-0.46-0.45-0.24
EPS (Basic, Before Extraordinaries)-0.31-0.33-0.73-0.61-0.41-0.46-0.45-0.24
EPS (Diluted)-0.31-0.33-0.73-0.61-0.41-0.46-0.45-0.24
EBITDA-34.29-31.05-63.93-49.41-27.70-31.10-31.22-18.19
Non-Operating Income (Expense)1.571.501.521.791.611.912.472.77
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.151.981.561.781.831.832.411.96
Shares Outstanding104.38104.3883.3485.5964.0364.0363.8263.81
Market Capitalization280.79475.15326.10276.46185.04137.66246.93417.93

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments136.85183.4586.79118.4370.1092.641.01118.07102.05
Short Term Receivables0.751.050.000.000.210.030.491.540.95
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets4.4210.803.382.311.905.283.251.731.93
Total Current Assets142.02195.3090.17120.7472.2097.954.75121.33104.92
Net Property, Plant & Equipment2.693.723.763.694.464.980.360.380.53
Total Investments and Advances0.610.611.341.341.341.340.000.000.00
Deferred Tax Assets0.620.71-------
Other Assets0.520.600.660.640.670.420.090.060.06
Total Assets146.46200.9395.94126.4178.67104.695.20121.76105.51
Short Term Debt Incl. Current Port. of LT Debt1.101.060.840.610.590.520.105.460.00
Accounts Payable5.222.421.281.691.662.633.543.590.00
Other Current Liabilities58.4720.877.398.416.595.842.264.267.29
Total Current Liabilities64.8024.369.5110.718.858.995.8913.317.29
Long Term Debt2.964.064.714.805.416.000.0015.1920.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.620.71-------
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities68.3729.1214.2115.5014.2514.995.8928.4927.29
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity78.08171.8181.72110.9064.4189.69-0.6993.2778.22
Total Shareholders Equity78.08171.8181.72110.9064.4189.69-0.6993.2778.22
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity78.08171.8181.72110.9064.4189.69-0.6993.2778.22
Total Liabilities & Stockholders Equity146.46200.9395.94126.4178.67104.695.20121.76105.51
Book Value Per Share0.942.691.862.563.645.84-1.3730.0234.14
Tangible Book Value Per Share0.942.691.862.563.645.84-1.3730.0234.14
Full-Time Employees71654226312873835
Price to Book Ratio2.201.242.151.512.973.670.781.981.42
Return on Assets-95.38-54.30-33.24-34.48-55.23-45.82-36.44-54.00-43.88
Return on Equity-132.59-63.58-38.36-40.33-65.72-59.28-49.97-71.57-52.04
Return on Invested Capital-204.42-45.83-42.75-30.56-72.52-44.39--56.58-52.97
Quick Ratio2.198.029.4911.288.1610.890.819.1214.39
Current Ratio2.198.029.4911.288.1610.890.819.1214.39

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-172.60-165.67-80.60-36.95-35.35-50.64-42.48-23.13-61.37
Depreciation0.300.350.320.310.270.330.150.080.26
Other Funds (Non Cash)6.325.033.355.695.845.462.160.139.03
Funds from Operations-165.99-160.30-76.94-30.95-29.24-44.85-40.17-22.93-52.08
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital10.0647.106.17-2.511.672.75-2.040.230.59
Cash from Operating Activities-155.92-113.20-70.76-33.46-27.57-42.10-42.21-22.70-51.49
Capital Expenditures-0.15-0.09-0.52-0.16-0.10-0.33-0.06-0.08-0.11
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments55.26100.40-84.8733.52-90.8624.50-23.490.00-6.76
Purchase of Investments-66.74-83.60-227.87-101.23-133.61-8.25-24.490.00-117.15
Sale Or Maturity of Investments122.00184.00143.00134.7542.7532.751.000.00110.39
Other Uses0.000.000.000.000.000.00-1.300.000.00
Other Sources0.000.000.000.000.000.0041.930.000.00
Cash from Investing Activities55.11100.31-85.3933.35-90.9624.1717.09-0.08-6.87
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock172.7765.09161.880.0375.2619.8993.5919.3966.91
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock172.7765.09161.880.0375.2619.8993.5919.3966.91
Proceedsfrom Stock Options172.7565.09161.810.000.000.0018.0019.3964.55
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities172.7765.09161.880.0375.2619.8993.5919.3966.91
Net Change in Cash71.9552.195.74-0.08-43.271.9568.47-3.398.55
Free Cash Flow-156.08-113.29-71.28-33.62-27.67-42.44-42.27-22.78-51.59
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments156.27200.38136.85175.44138.52157.53
Short Term Receivables0.270.790.751.000.981.06
Inventories0.000.000.000.000.000.00
Other Current Assets4.143.804.426.796.056.90
Total Current Assets160.67204.98142.02183.22145.56165.49
Net Property, Plant & Equipment3.692.422.692.983.273.50
Total Investments and Advances0.460.610.610.610.610.61
Deferred Tax Assets--0.62---
Other Assets0.480.500.520.540.560.58
Total Assets165.30208.51146.46187.35149.99170.18
Short Term Debt Incl. Current Port. of LT Debt1.201.061.101.151.131.10
Accounts Payable7.608.585.2211.104.172.27
Other Current Liabilities25.3738.1258.4732.8721.3518.76
Total Current Liabilities34.1747.7664.8045.1226.6522.13
Long Term Debt3.752.722.963.203.483.77
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.62---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities37.9250.4868.3748.3130.1325.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity127.38158.0378.08139.04119.85144.27
Total Shareholders Equity127.38158.0378.08139.04119.85144.27
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity127.38158.0378.08139.04119.85144.27
Total Liabilities & Stockholders Equity165.30208.51146.46187.35149.99170.18
Book Value Per Share1.221.510.941.621.872.25
Tangible Book Value Per Share1.221.510.941.621.872.25
Full-Time Employees--71---
Price to Book Ratio2.204.802.351.731.280.80
Return on Assets-109.49-87.67-95.38-64.96-51.55-45.52
Return on Equity-139.63-109.83-132.59-78.24-60.25-50.77
Return on Invested Capital-25.00-18.42-77.11-33.54-21.23-19.78
Quick Ratio4.704.292.194.065.467.48
Current Ratio4.704.292.194.065.467.48

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-32.78-29.61-62.50-47.71-26.18-29.28
Depreciation0.060.060.090.090.090.09
Other Funds (Non Cash)1.791.811.321.391.291.02
Funds from Operations-30.93-27.73-61.09-46.23-24.80-28.17
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-13.10-16.8822.5617.485.421.63
Cash from Operating Activities-44.03-44.61-38.53-28.75-19.38-26.54
Capital Expenditures-0.130.000.00-0.02-0.02-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-40.7829.0034.0033.0418.8614.50
Purchase of Investments-63.280.000.00-3.46-27.64-52.50
Sale Or Maturity of Investments22.5029.0034.0036.5046.5067.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-40.9129.0034.0033.0218.8414.45
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock-0.43108.11-0.2065.290.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.43108.11-0.2065.290.000.00
Proceedsfrom Stock Options-0.43108.10-0.2065.290.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.43108.11-0.2065.290.000.00
Net Change in Cash-85.3892.50-4.7369.55-0.54-12.09
Free Cash Flow-44.16-44.61-38.53-28.78-19.40-26.59

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.95%10.5M48.0M1.30M
2026-10-1530.55%14.7M48.0M1.31M
2026-09-3032.02%15.4M48.0M1.41M
2026-09-1528.90%13.9M48.1M1.74M
2026-08-3128.55%13.7M48.1M1.93M
2026-08-1428.00%13.4M48.0M2.08M
2026-07-3124.12%12.2M50.6M2.19M
2026-07-1522.36%11.3M50.6M2.18M
2026-06-3024.09%12.2M50.6M2.04M
2026-06-1520.82%10.5M50.6M1.74M
2026-05-2915.90%8.0M50.6M1.83M
2026-05-1517.28%8.7M50.6M4.36M
2026-04-3016.54%8.3M50.2M4.20M
2026-04-1512.99%7.3M56.4M4.29M
2026-03-3113.54%7.6M56.4M4.23M
2026-03-1312.65%7.3M57.4M4.07M
2026-02-2716.54%7.7M46.5M3.81M
2026-02-1319.31%9.0M46.5M1.23M
2026-01-3018.47%8.8M47.5M1.39M
2026-01-1518.00%8.6M47.7M1.41M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.750.203.9271900.000.720-0.0510.001
call5.000.000.050.057.1825740.000.525-0.0640.002
call7.500.003.500.153.8563.000.000.083-0.0140.001
put2.500.000.900.556.50911.000.00-0.280-0.0510.001
put5.000.102.702.504.9415.000.00-0.892-0.0110.001
put7.503.607.000.0020.3840.000.00-0.917-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-10-013Initial statement of beneficial ownership of securities2026-09-29SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-06-298-KCurrent report2026-06-29SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-198-KCurrent report2026-05-19SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-14SCHEDULE 13G/ASEC
2026-04-30SCHEDULE 13G/ASEC
2026-04-20ARSAnnual report to security holders. 2025-12-31SEC
2026-04-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-17SEC
2026-04-10PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-19SEC
2026-03-19S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-1910-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-198-KCurrent report2026-03-19SEC
2026-03-098-KCurrent report2026-03-09SEC
2026-03-02SCHEDULE 13D/ASEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-27SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-27SEC
2026-03-024Statement of changes in beneficial ownership of securities2026-02-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07166.89K100
2026-060000
2026-050000
2026-040000
2026-030000
2026-0225.55M400
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
DEERFIELD MANAGEMENT COMPANY, L.P.34.11%
Blue Owl Capital Holdings LP8.78%
BlackRock, Inc.5.44%
Defilade Capital Management, L.P.3.52%
DRIEHAUS CAPITAL MANAGEMENT LLC3.03%
VANGUARD CAPITAL MANAGEMENT LLC2.85%
RTW INVESTMENTS, LP2.46%
AQR CAPITAL MANAGEMENT LLC2.27%
MARSHALL WACE, LLP1.93%
DAFNA Capital Management LLC1.92%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.11%
iShares Russell 2000 ETF1.65%
Fidelity Enhanced Small Cap Core ETF0.78%
College Retirement Equities Fund - Total Global Stock Account0.73%
Fidelity Small Cap Index Fund0.70%
VANGUARD EXTENDED MARKET INDEX FUND0.67%
VANGUARD EXPLORER FUND0.63%
iShares Russell 2000 Growth ETF0.60%
VANGUARD RUSSELL 2000 INDEX FUND0.37%
iShares Biotechnology ETF0.35%

OakChart. LRMR. Cached 15 minutes.